Friday, Feb. 22, 2019
News Recap:
Time to Change Protocols for Post-SVR Monitoring for Liver Cancer?
In Memoriam: Anita York (May 27, 1953 - Feb. 7, 2019)
Funding via “Womens Wellness & Leadership Project” for women in BC living with HCV (&/or HIV)
MAVIRET™ 8 week, pan-genotypic HCV treatment, good for CKD & cirrhosis, covered in Ontario
No Time to Relax about Liver Cancer after HCV Treatment: Time to Change Monitoring
Current protocols for HCV post-SVR monitoring may need updating to expand screening for liver cancer to those without cirrhosis. This article is dedicated to all non-cirrhotics who have been diagnosed with liver cancer following treatment for HCV.
HepCBC's volunteer Webmaster, CD Mazoff, PhD (discourse analysis, McGill), is battling liver cancer (HCC). For several years, CD has faithfully published the online HepCBC Weekly Bull every Friday, showcasing Ca
Friday, Nov 9, 2018
News Recap:
Gilead Presents Latest Data from Viral Hepatitis Research Programs at The Liver Meeting® 2018
Gilead Sciences announced results from studies investigating Epclusa in chronic HCV patients with severe renal impairment undergoing dialysis and Harvoni in pediatric HCV patients aged three to five years. As well there was data from Gilead’s HBV cure development program.
High Prevalence of Cirrhosis in Adults with Chronic...
SAN FRANCISCO--(BUSINESS WIRE)--Nov 9, 2018--Gilead Sciences, Inc. (Nasdaq: GILD) today announced results from studies investigating Epclusa ® (sofosbuvir 400mg/velpatasvir 100mg) in chronic hepatitis C virus (HCV) infected patients with severe renal impairment undergoing dialysis and Harvoni ® (ledipasvir/sofosbuvir) in pediatric HCV patients aged three to five years, adding to the efficacy and safety profile of sofosbuvir-based regimens across diverse pa
Friday, August 24, 2018
News Recap:
Neuropsychiatric symptoms in hepatitis C patients resemble those of patients with autoimmune liver disease but are different from those in hepatitis B patients.
Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B vi...
Chronic fatigue, mood alterations and cognitive impairment are frequent accessory symptoms of HCV-infection. Fatigue and mood alterations have also been observed in autoimmune hepatitis (AIH) and primary biliary cholangitis (PBC), but not in hepatitis B virus (HBV)-infection, thus indicating an autoimmune response as possible cause of HCV-infection associated encephalopathy.
Data, however, are sparse. This study aims to prove that HCV patients feature sim
HepCBC has just released new pamphlets
on HBV and HCV in Hindi and Punjabi:
HBV Punjabi
HBV Hindi
HCV Hindi
HCV Punjabi
Be sure to check out all our pamphlets and posters at: http://hepcbc.ca/publications/pamphlets-posters/
Friday, February 9, 2018
News Recap:
Epidemiology:
CTAC Launches Campaign to End Hepatitis C in Canada. The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action.
#EASLmono: Expanding the conversation on hepatitis elimination. The recent European...
Elimination of infection in next 10 years possible through concerted action by policymakers and community leaders.
TORONTO, Feb. 6, 2018 /CNW/ - The Canadian Treatment Action Council (CTAC) has published a white paper entitled, "The time has come to eliminate hepatitis C in Canada," which summarizes the increasing gaps in Canada's response to the hepatitis C epidemic and identifies seven calls-to-action. CTAC is once again demonstrating its commitment to
According to research in Scientific Reports, the occurrence of age-related cataracts is associated with hepatitis B virus (HBV) and hepatitis C virus C (HCV) infection.
Liver dysfunction is a known significant risk factor for cataract formation, and the liver-damaging effects of HBV and HCV are hypothesised to play a role as well. To test this, associations between hepatitis and cataracts were tested along with any mediation of these associations by the l
